AIM ImmunoTech Inc. AIM

$0.12 +0.50% at last close
Market Cap$4.79 million
P/E Ratio—
Div Yield—
Volume459.7K
52-Week Range $0.12$2.88

Analyst Ratings

Consensus
Buy — 1 Buy · 0 Hold · 0 Sell (1 analysts)
Avg. Price Target
$7.00 (+5704.3% upside)

Full AIM forecast & analyst actions →

Key Stats

Today's Range
$0.12 – $0.13
50-Day Range
$0.12 – $0.23
52-Week Range
$0.12 – $2.88
Volume
460K shs
Average Volume
543K shs
Market Cap
$4.79 million
P/E Ratio
—
Dividend Yield
—

Short Interest

Short Interest
0.24%
Days to Cover
1.69

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).

Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees
21
Exchange
XASE
Listed
1995-11-02

Related Stocks

Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.